Skip to content

Investigation of the immunogenicity and durability of second COVID-19 vaccine booster dose and their associations with the background factors

Investigation of the immunogenicity and durability of second COVID-19 vaccine booster dose and their associations with the background factors - Investigation of the immunogenicity and durability of second COVID-19 vaccine booster dose and their associations with the background factors

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000048396
Enrollment
100
Registered
2022-07-20
Start date
2022-07-20
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Regardless of the type of disease

Interventions

None listed

Sponsors

Department of Pulmonology and Gerontology, Graduate School of Medicine, Yamaguchi University
Lead Sponsor
Department of Respiratory Medicine and Infectious Disease, Yamaguchi University Hospital
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) those who receive the second COVID-19 vaccine booster dose. 2) patients who visit or are admitted to or undergoing a home visit from Hofu Rehabilitation Hospital. 3) Persons who have received sufficient explanation regarding participation in this study with voluntary written consent provided by the person or their guardians after sufficient understanding.

Exclusion criteria

Exclusion criteria: 1) Those who do not wish to be vaccinated with second COVID-19 vaccine booster dose. 2) Those who are judged to be inappropriate for registration at the discretion of the doctor in charge.

Design outcomes

Primary

MeasureTime frame
Comparison of immune response between residents of long-term care facilities and outpatients at four weeks and 24 weeks after the second COVID-19 vaccine booster dose.

Secondary

MeasureTime frame
The assessment of associations vaccine immunogenicity at four weeks and 24 weeks after the second COVID-19 vaccine booster dose with the clinical background of participants.

Countries

Japan

Contacts

Public ContactTomoyuki Kakugawa

Graduate School of Medicine, Yamaguchi University Department of Pulmonology and Gerontology

kakugawa@yamaguchi-u.ac.jp0836-22-2196

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026